The present disclosure relates to separation and purification methods for a vaccine virus using affinity chromatography, and more particularly, to a purification method for a virus capable of obtaining a vaccine virus with a high purity and a high yield using affinity chromatography containing a vaccine virus-affinity resin.
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
B01D 15/38 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction spécifique non couverte par un ou plusieurs des groupes , p. ex. chromatographie d'affinité, chromatographie d'échange par ligand ou chromatographie chirale
The present disclosure relates to a pharmaceutical composition for preventing or treating non-alcoholic fatty liver disease or dyslipidemia comprising an aminoalkylbenzothiazepine derivative or a pharmaceutically acceptable salt thereof as an active ingredient.
A61K 31/554 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. clothiapine, diltiazem
3.
NOVEL N-(ISOPROPYL-TRIAZOLYL)PYRIDINYL)-HETEROARYL-CARBOXAMIDE DERIVATIVES AND USE THEREOF
The present disclosure relates to novel N-(isopropyl-triazolyl)pyridinyl)-heteroaryl-carboxamide derivatives or pharmaceutically acceptable salts thereof; a preparation method thereof; and use for preventing or treating an ASK-1 mediated disease comprising the same as an active ingredient.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
A61K 31/4427 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques
4.
NOVEL (ISOPROPYL-TRIAZOLYL)PYRIDINYL-SUBSTITUTED BENZOOXAZINONE OR BENZOTHIAZINONE DERIVATIVES AND USE THEREOF
The present disclosure relates to novel (isopropyl-triazolyl)pyridinyl-substituted benzooxazinone or benzothiazinone derivatives, or a pharmaceutically acceptable salt thereof; a preparation method thereof; and use for preventing or treating an ASK-1 mediated disease comprising the same as an active ingredient.
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61K 31/4427 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques
5.
PHARMACEUTICAL COMPOSITION COMPRISING ANTIPLATELET AGENT AND GASTRIC ACID SECRETION INHIBITOR
The present invention provides a pharmaceutical composition comprising clopidogrel or pharmaceutically acceptable salts thereof; and a compound of Formula 1 or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceutical composition of the present invention has an advantage of maintaining a medicinal effect of clopidogrel while preventing or treating a side effect of clopidogrel, i.e., gastrointestinal disorders.
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/4365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique ayant le soufre comme hétéro-atome du cycle, p. ex. ticlopidine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/43 - Composés contenant des systèmes cycliques thia-4 aza-1 bicyclo [3.2.0] heptane, c.-à-d. composés contenant un système cyclique de formule , p. ex. pénicillines, pénèmes
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
The present invention relates to a pharmaceutical composition comprising dapagliflozin or a pharmaceutically acceptable salt, hydrate, or solvate thereof; linagliptin or a pharmaceutically acceptable salt, hydrate, or solvate thereof; and an excipient, and a preparation method therefor. The pharmaceutical composition enhances a therapeutic effect on non-insulin dependent diabetes mellitus, with reduced side effects, and secure equivalent dissolution rates and non-clinical equivalence to respective agents including individual ingredients. The composition allows the minimization of tablet sizes and enhances the stability of product quality, as well, thereby improving patient's convenience for drug intake, and drug compliance. Therefore, the composition can be advantageously used as an effective prophylatic or therapeutic agent for non-insulin dependent diabetes mellitus.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/7034 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
8.
INTERMEDIATES FOR OPTICALLY ACTIVE PIPERIDINE DERIVATIVES AND PREPARATION METHODS THEREOF
A preparation method according to the present invention makes it possible to industrially produce large amounts of highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield by use of commercially available reagents and solvents. In addition, the use of novel intermediates according to the present invention makes it possible to produce highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield.
The present invention provides a novel compound having a protein kinase inhibition activity, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to the present invention show a protein kinase inhibition activity, thus being effective in preventing or treating diseases related to protein kinase, such as cancer, autoimmune disease, neurological disease, metabolic disease, infection or the like.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
The present invention relates to a medical infusion bag which comprises a main chamber, for accommodating an infusion solution, and an auxiliary chamber, for accommodating a liquid chemical, and enables simple mixing of the liquid chemical accommodated in the auxiliary chamber with the infusion solution accommodated in the main chamber, and thus facilitates the administration of the infusion solution as well as the additional administration of the liquid chemical.
The present invention relates to a medical infusion bag which comprises a main chamber, for accommodating an infusion solution, and an auxiliary chamber, for accommodating a liquid chemical, and enables simple mixing of the liquid chemical accommodated in the auxiliary chamber with the infusion solution accommodated in the main chamber, and thus facilitates the administration of the infusion solution as well as the additional administration of the liquid chemical.
The present disclosure relates to a pharmaceutical composition for preventing or treating non-alcoholic fatty liver disease or dyslipidemia comprising an aminoalkylbenzothiazepine derivative or a pharmaceutically acceptable salt thereof as an active ingredient.
A61K 31/554 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. clothiapine, diltiazem
The present disclosure relates to a composition for injection, which comprises a pharmaceutically acceptable salt of a compound represented by Formula 1 and one or more selected from mannitol, trehalose, lactose and glucose as a stabilizing agent, having improved stability.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The present disclosure relates to a method useful in mass production of a protein using microorganisms, by increasing the concentration of a nitrogen source at a low temperature of higher than or equal to 20°C but lower than 30°C. The method according to the present disclosure is useful for the expression of an active protein in high yield, which is suitably applicable to mass production while suppressing the production of unnecessary insoluble proteins from microorganisms.
The present disclosure relates to a method for separating and purifying an antibody or an antibody fragment thereof in high purity using affinity chromatography, and specifically, to a method for separating the antibody and antibody fragment thereof in high purity and purifying the same using an elution buffer capable of increasing stability for the enhancement of stability.
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
C07K 16/06 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux provenant de sérum
B01D 15/38 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction spécifique non couverte par un ou plusieurs des groupes , p. ex. chromatographie d'affinité, chromatographie d'échange par ligand ou chromatographie chirale
16.
METHOD FOR PURIFYING ANALOGOUS ANTIBODY USING CATION-EXCHANGE CHROMATOGRAPHY
The present disclosure relates to a method for separating impurities of analogous antibodies using cation-exchange chromatography, and more specifically, to a method for separating the single fragments and isoforms of analogous antibodies, which are produced during the process of producing analogous antibodies, and purifying only target antibody fragments in high purity and yield using an elution buffer for the cation-exchange chromatography.
B01D 15/36 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p. ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
17.
STABLE PREPARATION CONTAINING BORTEZOMIB AND PREPARATION METHOD THEREFOR
The present invention provides a bortezomib liquid preparation comprising: bortezomib or a pharmaceutically acceptable salt thereof; one or more sugar alcohols selected from the group consisting of mannitol, erythritol, sorbitol, isomalt, maltitol, xylitol and trehalose; and a solvent formed by mixing propylene glycol and polar solvents including water. The bortezomib liquid preparation of the present invention can be easily and commercially prepared, can prevent microbial contamination occurring during freeze-drying or reconstitution, exhibits an effect of improved administration convenience and stability, and since a sugar alcohol and propylene glycol are used, the ortezomib liquid preparation has no property abnormalities, such as discoloration or precipitate generation, in comparison with a conventional bortezomib-containing injectable liquid preparation, and meets standards.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
The present invention relates to a novel preparation containing a benzimidazole derivative. According to the present invention, a preparation for oral administration, comprising: a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof; and one or more disintegrating agents selected from the group consisting of croscarmellose sodium, sodium starch glycolate and a hydroxypropyl cellulose having a low degree of substitution, exhibits excellent storage stability and an effect of preventing deterioration of a dissolution rate, thereby being useful as a preparation for oral administration.
The present invention relates to an injectable composition and a method for preparing same, the injectable composition having a pH from 2.5 to 5.5 and comprising: pharmaceutically acceptable salts of a compound represented by chemical formula (1); and cyclodextrin.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
The present invention relates to pidolate and malate salts of a compound represented by chemical formula 1 and preparation methods therefor, wherein the compound has preventive and therapeutic uses for a disease mediated by acid pump antagonistic activity and is excellent in liquid-phase stability, solid-phase stability, solubility in water, precipitation stability, and hygroscopicity.
C07D 235/06 - BenzimidazolesBenzimidazoles hydrogénés avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement en position 2
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
The present invention relates to a composition for an injection and a preparation method therefor, wherein the composition comprises: a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof; cyclodextrin or a derivative thereof; and an organic acid.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
The present invention relates to a novel method for preparing a 5,7-difluorochroman-4-one derivative. The preparation method according to the present invention allows industrial mass production by using a generally usable reagent and solvent requiring no separate refinement process, having low production costs, and being under no environmental regulation and thus allows a 5,7-difluorochroman-4-one derivative to be efficiently produced.
C07C 67/10 - Préparation d'esters d'acides carboxyliques par réaction d'acides carboxyliques ou d'anhydrides symétriques avec des groupes ester ou avec une liaison carbone-halogène
C07C 67/307 - Préparation d'esters d'acides carboxyliques par modification de la partie acide de l'ester sans introduction d'un groupe ester par introduction d'atomes d'halogènePréparation d'esters d'acides carboxyliques par modification de la partie acide de l'ester sans introduction d'un groupe ester par substitution d'atomes d'halogène par des atomes d'autres halogènes
C07C 69/736 - Éthers le groupe hydroxyle de l'ester étant éthérifié par un composé hydroxylé dont le groupe hydroxyle est lié à un atome de carbone d'un cycle aromatique à six chaînons
C07C 69/712 - Éthers le groupe hydroxyle de l'ester étant éthérifié par un composé hydroxylé dont le groupe hydroxyle est lié à un atome de carbone d'un cycle aromatique à six chaînons
The present invention relates to a novel method for preparing a chromanol derivative. According to the present invention, unlike a conventionally known optically active reduction technique, a method for preparing a chromanol derivative having optical activity has advantages of: not needing an additional purification process since chromanol, to be prepared, exhibits a high optical purity; being favorable for mass production since no severe reaction conditions are contained and no dangerous reagents are used; and having an excellent preparation yield.
The present invention relates to a pharmaceutical composition containing: a first composition containing amlodipine or a pharmaceutically acceptable salt thereof and valsartan or a pharmaceutically acceptable salt thereof; and a second composition containing rosuvastatin or a pharmaceutically acceptable salt thereof. The pharmaceutical composition has excellent stability and a high elution rate of active ingredients, can be used in preventing and treating a cardiovascular disease, hypertension, arteriosclerosis, hyperlipidemia, and a complex disease thereof, in a more improved level, by alleviating side effects of conventional single preparations, by a synergistic combination of drugs having different mechanisms of action, and improves drug compliance.
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
A61K 31/41 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec plusieurs hétéro-atomes cycliques, l'un au moins étant l'azote, p. ex. tétrazole
A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
The present application relates to uses of a benzimidazole derivative compound for remedying and treating nocturnal acid breakthrough (NAB). The benzimidazole derivative compound according to the present application is capable of more effectively preventing or treating disorders related to gastric acid by effectively improving and treating symptoms of nocturnal acid breakthrough.
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
The present invention relates to a pharmaceutical composition and a method for preparing the same, the pharmaceutical composition comprising candesartan or candesartan cilexetil, amlodipine or a pharmaceutically acceptable salt thereof, and sugar alcohol, wherein the sugar alcohol is included in an amount of 50 weight % or less with respect to the total weight of the composition.
The present invention relates to a novel crystal form of a benzimidazole derivative and a preparation method thereof. The novel crystal form according to the present invention is not denatured under harsh lighting conditions for a long time, has low moisture absorption properties and significantly low static electricity induction properties, thereby allowing the crystal form to be formulated easily. In addition, the crystal form has very excellent inherent-stability so as to be useful for long-term storage.
C07D 407/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 235/06 - BenzimidazolesBenzimidazoles hydrogénés avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement en position 2
The present invention relates to a novel aminoalkyl benzothiazepine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition, containing the same as an active ingredient, for preventing or treating constipation.
C07D 281/10 - Cycles à sept chaînons comportant les hétéro-atomes en positions 1, 4 condensés avec des carbocycles ou avec des systèmes carbocycliques condensés avec un cycle à six chaînons
C07D 281/08 - Cycles à sept chaînons comportant les hétéro-atomes en positions 1, 4 condensés avec des carbocycles ou avec des systèmes carbocycliques
A61K 31/554 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. clothiapine, diltiazem
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
29.
SUSTAINED RELEASE FORMULATION OF METFORMIN AND METHOD FOR PREPARING SAME
The present invention relates to a gastric-retentive sustained release formulation of metformin, which is a non-insulin-dependent diabetes mellitus medicine, and a method for preparing the same. More particularly, the present invention relates to a gastric-retentive sustained release formulation, and a method for preparing the same, in which a sustained release granular product including a granule comprising metformin or a pharmaceutically acceptable salt thereof and a swellable polymer is produced, a water-insoluble polymer film being coated on the granule surface, and thus the release of drug can be effectively controlled while using a small quantity of the polymer, and the granular product is mixed and formulated with a superdinsintegrant which controls the gelation velocity to produce a hydrogel so that a tablet comprising the drug can be quickly swelled in the early stage.
The present invention relates to a biomarker for predicting sensitivity to a protein kinase inhibitor and a use thereof, and provides a marker for predicting sensitivity to a protein kinase inhibitor, a composition, a kit, and a prediction method. According to the present invention, an effect of predicting sensitivity to a protein kinase inhibitor is excellent, and thus the present invention can be useful for cancer treatment.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
31.
NOVEL AMINO-PHENYL-SULFONYL-ACETATE DERIVATIVE AND USE THEREOF
The present invention relates to: a novel amino-phenyl-sulfonyl-acetate derivative or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating diabetes, containing the same as an active ingredient.
C07C 317/44 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde et des groupes carboxyle liés au même squelette carboné
C07C 317/48 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde et des groupes carboxyle liés au même squelette carboné le squelette carboné étant substitué de plus par des atomes d'azote liés par des liaisons simples, ne faisant pas partie de groupes nitro ou nitroso
C07C 317/14 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde liés à des atomes de carbone de cycles aromatiques à six chaînons
The present invention relates to a stabilized pemetrexed formulation, and more particularly to a stabilized pemetrexed formulation comprising acetylcysteine as antioxidant and a citrate salt as buffer.
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61J 1/05 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques pour recueillir, stocker ou administrer du sang, du plasma ou des liquides à usage médical
33.
ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITE FORMULATION CONTAINING BISOPROLOL AND ROSUVASTATIN
The present invention relates to an orally administered pharmaceutical composite formulation containing bisoprolol and rosuvastatin and a method for manufacturing same. The orally administered pharmaceutical composite formulation, according to the present invention, effectively prevents and treats hypertension, angina, and hypercholesterolemia, and the reduction in stability of the formulation is improved by a reaction between two active ingredients, which provides excellent storage stability, thereby improving drug administration convenience of the patient and being useful in the treatment of hypertension, angina, and hypercholesterolemia.
The present invention relates to a solifenacin preparation containing solifenacin or a pharmaceutically acceptable salt thereof, an antioxidant, and a binder, which is manufactured via direct compression. Compared to the preparations manufactured via conventional wet granulation process, the preparation of the present invention can be manufactured by a simplified process such as direct compression, and has improved content uniformity, mixing degree, etc., even when the preparation is manufactured by high speed tableting.
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
36.
Stable pharmaceutical composition comprising solifenacin, and method for preparing the same
The present invention relates to a solifenacin preparation containing solifenacin or a pharmaceutically acceptable salt thereof, an antioxidant, and a binder, which is manufactured via direct compression. Compared to the preparations manufactured via conventional wet granulation process, the preparation of the present invention can be manufactured by a simplified process such as direct compression, and has improved content uniformity, mixing degree, etc., even when the preparation is manufactured by high speed tableting.
A61K 31/4725 - Isoquinoléines non condensées, p. ex. papavérine contenant d'autres hétérocycles
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
The present invention relates to a method for preparing an aqueous formulation of moxifloxacin and an aqueous formulation of moxifloxacin prepared thereby and, more specifically, to a method for preparing an aqueous formulation of moxifloxacin, comprising the step of dissolving moxifloxacin free base in a NaCl aqueous solution, and an aqueous formulation of moxifloxacin prepared thereby. The present invention has an effect of providing: an aqueous formulation of moxifloxacin which is suitable for mass production because the aqueous formulation of moxifloxacin exhibits excellent quality, content uniformity and accuracy without moisture absorption problems during the preparation process and storage, and because the preparation process is simple; and a method for preparing the same.
The present invention relates to a method for purifying darbepoetin alfa by selectively separating only a structural subtype having a high content of sialic acid from a mixture of structural subtypes of darbepoetin alfa having various contents of sialic acid. Since the method of the present invention is a novel method for purifying darbepoetin alfa which can be conveniently and simply produced, it is possible to remarkably increase productivity due to process efficiency improvement, as well as to yield high purity darbepoetin alfa when mass-producing darbepoetin alfa according to the present invention.
The present invention relates to a medicinal herb extract using a malt enzyme liquid and a preparation method therefor and, more specifically, to a method for preparing a medicinal herb extract having appetite and immunity increasing effects, the method comprising: reacting a malt enzyme liquid with a herbal medicine; and extracting the reacted malt enzyme liquid and herbal medicine. Accordingly, the method for preparing a medicinal herb extract using a malt enzyme liquid enables carbohydrate and protein components of the herb medicine to be hydrolyzed so as to have low molecular weights, thereby providing the effect of increasing the absorption ratio in the human body.
The present invention relates to a long-acting human growth hormone NexP-hGH protein and its production method. More specifically, it relates to a specific isoform of long-acting human growth hormone NexP-hGH protein in which human growth hormone is fused with a highly glycosylated alpha-1 antitrypsin mutant whereby long-acting properties in vivo are increased. The present invention also relates to a high-purity purification method for NexP-hGH, which includes the steps of: (a) carrying out anion-exchange resin chromatography on a biological emulsion comprising NexP-hGH in which human growth hormone is fused with an alpha-1 antitrypsin mutant; (b) carrying out hydrophobic resin chromatography on the biological emulsion comprising NexP-hGH, or on the eluate produced in step (a); and (c) carrying out affinity chromatography, entailing packing with a resin to which anti-alpha-1 antitrypsin antibody fragments are attached, on the biological emulsion comprising NexP-hGH and on the eluate produced in step (a) or step (b).
The present invention relates to a pyrrolopyridazine derivative represented by chemical formula 1 of the detailed description, or a pharmaceutically acceptable salt thereof. According to the present invention, a compound and a pharmaceutically acceptable salt thereof inhibit the activity of a protein kinase, and thus are useful for preventing or treating diseases related thereto.
The present invention relates to a complex formulation containing metformin used in the treatment of non-insulin dependent diabetes and an HMG-CoA reductase inhibitor used in the treatment of dyslipidemia. The present invention provides a complex formulation and a method for preparing the complex formulation, wherein the complex formulation contains metformin and an HMG-CoA reductase inhibitor, and has effectively improved stability by securing the stable release of respective active ingredients and blocking physical and chemical reactions between the active ingredients.
The present invention provides a method for preparing a compound with a benzimidazole structure with an excellent yield using a low-cost starting material, not requiring an additional separation process, or not using a dangerous reagent during the manufacturing process. Furthermore, the present invention also provides an intermediate and a final product produced by the preparing method.
C07D 235/08 - Radicaux ne contenant que des atomes d'hydrogène et de carbone
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
The present invention relates to a high-purity purification method for darbepoetin alpha having a high content of sugar chains and, particularly, to a purification method for darbepoetin alpha comprising the steps of: (a) eluting a fraction comprising darbepoetin alpha by applying a biological emulsion comprising darbepoetin alpha to blue resin chromatography; (b) eluting a fraction comprising darbepoetin alpha by applying an eluate produced from step (a) to hydroxyapatite resin chromatography; and (c) eluting a fraction comprising darbepoetin alpha by applying an eluate produced from step (b) to anion-exchange resin chromatography.
The present invention relates to a continuous process for preparing microspheres and microspheres prepared thereby, and in particular, a process for preparing microspheres comprising steps of injecting a first emulsion and a second emulsion at the same time to form microspheres instantaneously, applying high pressure to the microspheres formed, and injecting the microspheres into an agitator, wherein the steps can be carried out continuously, and microspheres prepared thereby.
When microspheres are prepared using the method of the present invention, scale variables, which have been the biggest disadvantage in existing preparation methods of microspheres, can be significantly reduced, drug encapsulation efficiency can be improved, and small and uniform particles can be obtained.
The present invention relates to a stabilized pemetrexed preparation, and more specifically to a stabilized pemetrexed preparation containing acetylcysteine as an antioxidant and sodium citrate as a buffer. Furthermore, the present invention relates to a pemetrexed preparation which is contained within a sealed container, and which contains as an active ingredient pemetrexed or pharmaceutically acceptable salt thereof, wherein the amount of oxygen in the headspace within the container is 3 v/v% or less.
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
Laurus nobilis leaf extract, it has a remarkably excellent effect of lowering blood concentrations of alcohol and acetaldehyde. Its hangover-preventing and treating effects were confirmed by behavioral tests, and thus the composition can be widely applied to foods, drugs, or functional health foods which can be effectively used for preventing and treating hangover.
The present invention relates to a method of preparing microspheres by using a polymer having a sol-gel transition property and microspheres prepared thereby, and more particularly, to a method of preparing microspheres by using a polymer having a sol-gel transition property and microspheres prepared thereby capable of preventing a solvent in a polymer solution for a carrier from being rapidly diffused to the aqueous medium before formation of the microspheres to reduce porosity of the microspheres and reduce surface roughness of the microspheres in order to obtain microspheres having a sphere shape, and increasing an encapsulation ratio of a bioactive substance, by using a polymer having a sol-gel transition property as a surfactant included in an aqueous medium into which a primary emulsion is injected and gelating a secondary emulsion formed after injecting the primary emulsion using the sol-gel transition property of the polymer used as the surfactant.
The present invention relates to a formulation of voglibose or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof which is provided for the reduction, in a substantially equivalent or increased amount compared to single administration of metformin, of HbAlc levels, fasting and postprandial blood glucose levels and postprandial blood glucose variation, or glycemic variability and also the reduction of the frequency of hypoglycemia, cardiovascular complications, and gastrointestinal complications in a patient with no prior experience of anti-diabetes medication or a patient in the early stage of type 2 diabetes showing a HbAlc (%) level of 7 to 11%, and ultimately, is able to effectively treat diabetes in patients in the early stage of type 2 diabetes and to minimize adverse effects, side-effects, and risk of complications.
A61K 31/133 - Amines, p. ex. amantadine ayant des groupes hydroxyle, p. ex. sphingosine
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
50.
COMPOSITION CONTAINING, AS ACTIVE INGREDIENTS, MENISPERMUM DAURICUM, EXTRACT OF MENISPERMUM DAURICUM, SLIME OF MENISPERMUM DAURICUM, OR EXTRACT OF MALT ENZYME LIQUID OF MENISPERMUM DAURICUM FOR PREVENTING OR TREATING ANOREXIA
The present invention relates to a pharmaceutical composition for preventing or treating anorexia, a health functional food composition, and an animal feed additive composition for promoting appetite, the compositions containing, as active ingredients, Menispermum dauricum, an extract of Menispermum dauricum, a slime of Menispermum dauricum, or an extract of a malt enzyme liquid of Menispermum dauricum. The Menispermum dauricum, the extract of Menispermum dauricum, the slime of Menispermum dauricum, or the extract of the malt enzyme liquid of Menispermum dauricum is pharmaceutically usable as a composition for promoting appetite, or for preventing or treating anorexia and eating disorders, and is also useful as a health functional food. Further, a herbal medicine extract according to the present invention can be easily used as an animal feed additive for promoting appetite.
The present invention relates to a stabilized pemetrexed formulation, and more particularly to a stabilized pemetrexed formulation comprising acetylcysteine as antioxidant and a citrate salt as buffer.
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
The present invention relates to: a method for preparing a high-purity monomer of a NexP-hGH protein, which is a long-acting human growth hormone, using anion-exchange resin chromatography; and a monomer of a NexP-hGH protein prepared by the method.
The present invention relates to a composition comprising saikosaponin A, berberine, and licoisoflavone B for preventing or treating gastric diseases, and more particularly, to a pharmaceutical composition for preventing or treating gastric diseases, to a food composition for preventing or treating gastric diseases, to a method for preparing the composition, and to a method for treating gastric diseases using the composition, wherein the pharmaceutical composition and the food composition comprise 15 mg/g to 50 mg/g of saikosaponin A, 30 mg/g to 100 mg/g of berberine, and 0.5 mg/g to 5 mg/g of licoisoflavone B.
A61K 31/70 - Hydrates de carboneSucresLeurs dérivés
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. quinolizines, naphtyridines, berbérine, vincamine
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
54.
PROTEIN KINASE INHIBITOR COMPRISING PYRIDINE DERIVATIVES
The compound according to the present invention and the pharmaceutically acceptable salts thereof inhibit the activity of protein kinase, and therefore, can be effectively used in preventing or treating diseases relating to the activity of protein kinase.
A61K 31/4535 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle, p. ex. pizotifène
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
55.
PHARMACEUTICAL COMBINED FORMULATION COMPRISING METFORMIN AND HMG-COA REDUCTASE INHIBITOR
The present invention relates to a pharmaceutical combined formulation comprising metformin and an HMG-CoA reductase inhibitor, and a preparation method therefor, and more specifically, to a pharmaceutical combined formulation, and a preparation method therefor, the pharmaceutical combined formulation comprising: a first composition comprising a core layer comprising metformin or a pharmaceutically acceptable salt thereof and a water-insoluble polymer, and a hydrophobic base coating layer formed on the core; and a second composition comprising an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof and a stabilizer.
The present invention relates to a long-acting human growth hormone NexP-hGH protein which is highly glycosylated and highly long acting in vivo, and relates to a production method for same. More specifically, the present invention relates to a specific isoform of long-acting human growth hormone NexP-hGH protein in which human growth hormone is fused with a highly glycosylated alpha-1 antitrypsin mutant whereby long-acting properties in vivo are increased, and relates to a production method for same. Insofar as the sustained human growth hormone production method is concerned, the present invention also relates to a high-purity purification method for NexP-hGH, the method specifically comprising the steps of: (a) carrying out anion-exchange resin chromatography on a biological emulsion comprising NexP-hGH which is a long-acting human growth hormone in which human growth hormone is fused with an alpha-1 antitrypsin mutant; (b) carrying out hydrophobic resin chromatography on the biological emulsion comprising NexP-hGH, or on the eluate produced in step (a); and (c) carrying out affinity chromatography, entailing packing with a resin to which anti alpha-1 antitrypsin antibody fragments are attached, on the biological emulsion comprising NexP-hGH which is a long-acting human growth hormone, and on the eluate produced in step (a) or step (b).
The present invention relates to a stabilized liquid preparation for injection containing pemetrexed or a pharmaceutically acceptable salt thereof, and more particularly, to a liquid preparation for injection containing pemetrexed, which has improved stability as it comprises one or more types of stabilizing agent(s) selected from sodium sulfide and sodium sulfite. [Representative figure:] Fig. 1.
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
58.
SUSTAINED-RELEASE PREPARATION USING GASTRORETENTIVE DRUG DELIVERY SYSTEM
The present invention relates to a sustained-release preparation which limits release and absorption of drug using a gastroretentive system and which can minimize the effect of in vivo environment, and to a method for preparing the sustained-release preparation. More particularly, the sustained-release preparation according to the present invention comprises a swellable polymer, and a first controlled-release base and a second controlled-release base. Therefore, the sustained-release preparation of the present invention may adjust the degree of swelling and floating of a polymer in order to effectively achieve gastric retention. Thus, drugs may ultimately be retained in the gastrointestinal tract over a long period of time, and the bioavailability of drugs may be improved in order to enable once-a-day administration.
The present invention relates to an improved method of preparing adefovir dipivoxil of Formula 1. The method of the present invention is characterized by using dimethylsulfoxide as a reaction solvent, and comprises a process of preparing adefovir dipivoxil of Formula 1 by allowing adefovir of Formula 2 to react with chloromethylpivalate at a reaction temperature of 30 to 50° C. under the presence of dimethylsulfoxide and triethylamine solvents.
C07F 9/6561 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle contenant des systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un carbocycle ou un système carbocyclique commun, avec ou sans autres hétérocycles non condensés
C07D 473/34 - Atome d'azote lié en position 6, p. ex. adénine
C07F 9/28 - Composés du phosphore à une ou plusieurs liaisons P—C
brevets
